On March 29, 2019 Bicycle Therapeutics, a biotechnology company pioneering a new class of therapeutics based on its proprietary bicyclic peptide (Bicycle) product platform, reported that Bicycle scientists have been selected to present two oral presentations at the American Association for Cancer Research (AACR) (Free AACR Whitepaper) Annual Meeting in Atlanta (Press release, Bicycle Therapeutics, MAR 29, 2019, View Source [SID1234534762]). These presentations will focus on preclinical programs that have shown target-dependent anti-tumor activity across a range of patient-derived Nectin-4 and EphA2 expressing cancer models.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"Because of their small size and profound efficacy, Bicycle’s toxin conjugates are able to do what many previous antibody drug conjugate approaches could not," said Nicholas Keen, Ph.D., Chief Scientific Officer of Bicycle Therapeutics. "Preclinical data from both our BT5528 and BT8009 programs show target-dependent anti-tumor activity across a range of EphA2-expressing and Nectin-4-expressing cancer models, respectively, and we’re proud that AACR (Free AACR Whitepaper) has chosen to highlight our work."

In addition, Bicycle has also been selected to present a poster on its CD137 program, intended to activate cytotoxic T-cells, a type of cell used in the body’s immune response.

Added Keen: "We believe Bicycle’s work on CD137 has produced the first fully-synthetic immune oncology modulators, which may confer several advantages over existing modalities because of the multivalency and pharmacokinetic characteristics of Bicycles."

Details on Bicycle’s presentations at the 2019 AACR (Free AACR Whitepaper) Annual Meeting are as follows:

Oral Presentation Title: BT8009: A bicyclic peptide toxin conjugate targeting Nectin-4 (PVRL4) displays efficacy in preclinical tumor models
Presenter: Michael Rigby, Ph.D., project leader for BT8009, a Nectin-4 targeted Bicycle Toxin Conjugate
Session Title: Novel Therapeutics
Abstract: #4479
Date and Time: April 2, 2019, 3:00 p.m. – 5:00 p.m. EDT

Oral Presentation Title: BT5528, an EphA2-targeting Bicycle Toxin Conjugate (BTC): Profound efficacy without bleeding and coagulation abnormalities in animal models
Presenter: Gavin Bennett, Ph.D., Director of Preclinical Development and project leader for BT5528, an EphA2 targeted Bicycle Toxin Conjugate
Session Title: Novel Therapeutics
Abstract: #4481
Date and Time: April 2, 2019, 3:00 p.m. – 5:00 p.m. EDT

Poster Presentation Title: Activation of CD137 using multivalent and tumor-targeted Bicyclic peptides
Presenter: Johanna Lahdenranta, Ph.D., Director of In Vivo Pharmacology
Session Title: Novel Immunomodulatory Agents 1
Abstract: #3257
Date and Time: April 2, 2019, 8:00 a.m. – 12:00 p.m. EDT